Researchers from Osaka University unveil a radioactive monoclonal antibody that can both diagnose and treat a deadly type of pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide, with a five-year survival rate of less than 10%. Many PDAC tumours in early stage go undetected because they are not found using conventional imaging methods, including fluorodeoxyglucose positron emission tomography (PET) scans. To more efficiently combat this pancreatic cancer, a team led by researchers at Osaka University is combining diagnostic and therapeutic procedures into a single integrated process, called “theranostics.”
In an article recently published in Journal of Nuclear Medicine, the team has developed a “radio-theranostics” strategy that uses a new radioactive antibody to target glypican-1 (GPC1), a protein highly expressed in PDAC tumours. Theranostics, particularly radio-theranostics, has been receiving increasing attention because, by radiolabelling the compounds used to target certain molecules in cancer cells, diagnosis and treatment can be carried out sequentially.
“We decided to target GPC1 because it is overexpressed in PDAC but is only present in low levels in normal tissues,” explained Tadashi Watabe, lead author of the study.
The team used a monoclonal antibody (mAb), an antibody designed to target a certain molecule, to target GPC1. The mAb could be labelled with radioactive zirconium (Zr) or radioactive astatine (At). They worked with a xenograft mouse model, which involved human pancreatic cancer cells being injected into a mouse that developed into a full tumour that could be experimentally treated and monitored. These mice were intravenously administered Zr-labeled GPC1 mAb. They were also given At-labeled GPC1 mAb to examine the anti-tumour effects.
“We monitored Zr-GPC1 mAb internalisation over seven days with PET scanning,” explained Kazuya Kabayama, the second author of the article. “There was strong uptake of the mAb into the tumours, suggesting that this method could support tumour visualisation. We confirmed that this was mediated by its binding to GPC1, as the xenograft model that had GPC1 expression knocked out showed significantly less uptake.”
The researchers next tested this model with alpha therapy using At-GPC1 mAb, a method that could support radioactive label-based delivery of a therapeutic molecule to its target. Administration of At-GPC1 mAb resulted in DNA double-strand break induction in the cancer cells, as well as significantly reduced tumour growth. Control experiments showed that these anti-tumour effects did not occur when mAb internalisation was blocked. Additionally, non-radiolabelled GPC1 mAb did not induce these effects.
“Both radiolabelled versions of the GPC1 mAb we examined showed promising results in PDAC,” said Watabe. “Zr-GPC1 mAb showed high tumoural uptake, while At-GPC1 mAb could be used for targeted alpha therapy to support suppression of PDAC tumour growth.” These highly impactful data demonstrate the potential for using a theranostics approach in PDAC, a disease in dire need of new diagnostic and therapeutic options. In the future, this could lead to early detection of PDAC with PET imaging and systemic treatment with alpha therapy.